✨
AI Summary & Key Takeaways
AI Insight⚡ TL;DR(Too Long; Didn't Read)
This case supports that clinicians should be attentive for immune-related adverse events after use of immune checkpoint inhibitors.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Nivolumab is a monoclonal antibody against programmed cell death protein-1 which is assessed in the group of immune checkpoint inhibitors.
📊
Key Findings & Data:In this article, we report a 38-year-old male patient diagnosed with seronegative arthritis after nivolumab therapy.
💡
Conclusion & Impact:This case supports that clinicians should be attentive for immune-related adverse events after use of immune checkpoint inhibitors.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Özet
Nivolumab is a monoclonal antibody against programmed cell death protein-1 which is assessed in the group of immune checkpoint inhibitors. It may lead to immune-related adverse events. In this article, we report a 38-year-old male patient diagnosed with seronegative arthritis after nivolumab therapy. This case supports that clinicians should be attentive for immune-related adverse events after use of immune checkpoint inhibitors.
🔖
Cite This Article
ÇOLAK, S., OMMA, A. (2019). Nivolumab Induced Seronegative Arthritis in a Patient With Refractory Hodgkin’s Lymphoma. art, Cilt: 34 - Sayı: 1, 112–114. https://ajindex.com/articles/149682